Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.

Autor: Roloff GW; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Aldoss I; Division of Leukemia, Department of Hematology and Hematopoitic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Kopmar NE; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Lin C; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC., Dekker SE; Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Gupta VK; Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA., O'Connor TE; Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL., Jeyakumar N; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Muhsen IN; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX., Valtis Y; Memorial Sloan Kettering Cancer Center, New York, NY., Ahmed N; Memorial Sloan Kettering Cancer Center, New York, NY., Zhang A; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Miller K; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Dykes KC; Department of Medicine, Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA., Ahmed M; Cedars-Sinai Medical Center, Los Angeles, CA., Chen EC; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Mercadal S; Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Schwartz M; University of Colorado Anschutz School of Medicine, Aurora, CO., Tracy SI; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Dholaria B; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Mukherjee A; University of Arkansas Medical Center, Little Rock, AK., Battiwalla M; Sarah Cannon Transplant and Cell Therapy Network, Nashville, TN., Logan AC; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA., Ladha A; Department of Hematology, Norris Cancer Center, University of Southern California, Los Angeles, CA., Guzowski C; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Hoeg RT; Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA., Hilal T; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ., Moore J; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Connor MP; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Hill LC; Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital, Houston, TX., Tsai SB; Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL., Sasine JP; Cedars-Sinai Medical Center, Los Angeles, CA., Solh MM; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Kota VK; Georgia Cancer Center, Augusta University, Augusta, GA., Koura D; Department of Medicine, Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA., Veeraputhiran M; University of Arkansas Medical Center, Little Rock, AK., Leonard JT; Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Frey NV; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Park JH; Memorial Sloan Kettering Cancer Center, New York, NY., Luskin MR; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Galal A; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC., Pullarkat V; Division of Leukemia, Department of Hematology and Hematopoitic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Stock W; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Cassaday RD; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Shah BD; Moffitt Cancer Center, Tampa, FL., Faramand R; Moffitt Cancer Center, Tampa, FL., Muffly L; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 17, pp. JCO2400321. Date of Electronic Publication: 2024 Oct 17.

Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL.

Autor: Aldoss I; City of Hope National Medical Center, Duarte, California, United States., Roloff GW; The University of Chicago, Chicago, Illinois, United States., Faramand RG; Moffitt Cancer Center, Tampa, Florida, United States., Kopmar NE; University of Washington, Seattle, Washington, United States., Lin C; Duke University School of Medicine, Durham, North Carolina, United States., Advani AS; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States., Dekker SE; Fred Hutchinson Cancer Center / University of Washington, Seattle, Washington, United States., Gupta VK; UCLA, Los Angeles, California, United States., O'Connor TE; Loyola University Medical Center, Maywood, Illinois, United States., Jeyakumar N; Stanford University, Stanford, California, United States., Muhsen IN; Baylor College of Medicine, Houston, Texas, United States., Valtis YK; Memorial Sloan Kettering Cancer Institute, New York city, New York, United States., Zhang A; Stanford University School of Medicine, Palo Alto, California, United States., Miller K; Stanford University School of Medicine, Stanford, California, United States., Sutherland KC; Stanford University School of Medicine, Stanford, California, United States., Dykes KC; University of California, San Diego, La Jolla, California, United States., Ahmed M; Cedars Sinai Medical Center, Houston, Texas, United States., Chen EC; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Zambrano H; Sarah Cannon Cancer Institute, Nashville, Tennessee, United States., Bradshaw D; Georgia Cancer Center at Augusta University, Augusta, Georgia, United States., Mercadal S; University of Utah/ Huntsman Cancer Hospital, Salt Lake City, Utah, United States., Schwartz MS; University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States., Tracy SI; University of Minnesota, Minneapolis, Minnesota, United States., Dholaria B; Vanderbilt University Medical Center, Nashville, Tennessee, United States., Kubiak MJ; Georgia Cancer Center of Augusta University, Augusta, Georgia, United States., Mukherjee A; Oncology Hematology Care, Cincinnati, Ohio, United States., Majhail NS; Sarah Cannon Cancer Institute, Nashville, Tennessee, United States., Battiwalla M; Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, Tennessee, United States., Mountjoy L; Colorado Blood Cancer Institute, Denver, Colorado, United States., Malik SA; Texas Transplant Institute, Austin, Texas, United States., Mathews J; Sarah Cannon Transplant and Cellular Therapy Program, Dallas, Texas, United States., Shaughnessy PJ; Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital San Antonio, TX, San Antonio, Texas, United States., Logan A; University of California San Francisco, San Francisco, California, United States., Ladha A; University of Southern California, Los Angeles, California, United States., Stefan M; Cleveland Clinic, Cleveland, Ohio, United States., Guzowski C; Northside Hospital, Atlanta, Georgia, United States., Hoeg RT; UC Davis, Sacramento, California, United States., Hilal T; Mayo Clinic, Phoenix, Arizona, United States., Moore J; University of Rochester Medical Center, Rochester, New York, United States., Connor M; University of Pennsylvania, Philadelphia, Pennsylvania, United States., O'Dwyer KM; University of Rochester Medical Center, Rochester, New York, United States., Hill LC; Baylor College of Medicine, Houston, Texas, United States., Tsai SB; Loyola University Medical Center, Maywood, Illinois, United States., Sasine JP; Cedars-Sinai Medical Center, Los Angeles, California, United States., Solh MM; The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States., Lee CJ; University of Utah; Huntsman Cancer Institute, United States., Kota V; Georgia Cancer Center at Augusta University, Augusta, Georgia, United States., Koura D; University of California, San Diego, La Jolla, California, United States., Veeraputhiran M; University of Arkansas Medical Center, Little Rock, Arkansas, United States., Blunk B; Sarah Cannon Cancer Institute, Nashville, Tennessee, United States., Oliai C; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States., Leonard JT; Oregon Health Sciences, Portland, Oregon, United States., Frey NV; Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States., Park JH; Memorial Sloan-Kettering Cancer Center, New York, New York, United States., Luskin MR; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Bachanova V; University of Minnesota, Minneapolis, Minnesota, United States., Galal A; Atlantic Health Network, Morristown, New Jersey, United States., Bishop MR; University of Chicago, Chicago, Illinois, United States., Stock W; University of Chicago, Chicago, Illinois, United States., Cassaday RD; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Pullarkat VA; City of Hope Medical Center, Duarte, California, United States., Shah BD; Moffitt Cancer Center, Tampa, Florida, United States., Muffly L; Stanford University, Stanford, California, United States.

Publikováno v: Blood advances [Blood Adv] 2024 Aug 02. Date of Electronic Publication: 2024 Aug 02.

Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.

Autor: Abraham IE; UChicago Medicine Ingalls Memorial Hospital, Harvey, IL., Rauscher GH; Division of Epidemiology and Biostatistics UIC, University of Illinois Cancer Center, Chicago, IL., Patel AA; Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, IL., Pearse WB; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Rajakumar P; Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center, Chicago, IL., Burkart M; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Aleem A; Division of Hematology and Oncology, Loyola University Medical Center, Maywood, IL., Dave A; Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center, Chicago, IL., Bharadwaj S; Division of Hematology and Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; and., Paydary K; Division of Hematology and Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; and., Acevedo-Mendez M; Division of Epidemiology and Biostatistics UIC, University of Illinois Cancer Center, Chicago, IL., Goparaju K; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Gomez R; Division of Hematology and Oncology, Loyola University Medical Center, Maywood, IL., Carlson K; Division of Hematology and Oncology, Loyola University Medical Center, Maywood, IL., Tsai SB; Division of Hematology and Oncology, Loyola University Medical Center, Maywood, IL., Quigley JG; Division of Hematology and Oncology UIC, University of Illinois Cancer Center, Chicago, IL., Galvin JP; Division of Epidemiology and Biostatistics UIC, University of Illinois Cancer Center, Chicago, IL., Zia M; Division of Hematology and Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; and., Larson ML; Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center, Chicago, IL., Berg S; Division of Hematology and Oncology, Loyola University Medical Center, Maywood, IL., Stock W; Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, IL., Altman JK; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Khan I; Division of Hematology and Oncology UIC, University of Illinois Cancer Center, Chicago, IL.

Publikováno v: Blood [Blood] 2022 Apr 07; Vol. 139 (14), pp. 2212-2226.

Call for Special Issue Papers: Big Data Analytics in Industrial Intelligence .

Autor: Tsai SB; School of Business, WUYI University, China., Wu CH; Minghsin University of Science and Technology, Hsinchu, Taiwan., Qi L; School of Computer Science, Qufu Normal University, China.

Publikováno v: Big data [Big Data] 2022 Feb; Vol. 10 (1), pp. 87-88. Date of Electronic Publication: 2022 Jan 13.